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This paper describes the results of second-line drug 
(SLD) susceptibility tests among multidrug-resistant 
tuberculosis (MDR TB) cases reported in 20 European 
countries aiming to identify extensively drug-resistant 
tuberculosis (XDR TB) cases. A project on molecu-
lar surveillance of MDR TB cases was conducted by 
EuroTB and the National Institute for Public Health 
and the Environment (RIVM) from 2005 to 2007. 
Information on drug susceptibility testing (DST) was 
provided to this project and case-based data on MDR 
TB cases were reported on a quarterly basis by 20 
countries of the World Health Organization’s European 
Region, including 15 European Union Member States. 
Data included SLD susceptibility test results, ena-
bling a retrospective description of XDR TB cases noti-
fied between 2003 and 2007. In 18 countries DST was 
performed for two or more of the SLD included in the 
XDR TB definition. The proportion of MDR TB isolates 
tested for SLD varied widely between countries (range 
20 to 100 percent). In the 18 countries, 149 (10%) XDR 
TB cases were reported among MDR TB cases with 
available DST results for SLD. Sixteen additional MDR 
TB cases were reported by the MDR TB surveillance 
system when compared with the number of routinely 
reported MDR TB cases to EuroTB in ten countries with 
representative data reported during three consecutive 
years (2003-2005). To counter the threat of XDR TB in 
Europe, a standardised approach to XDR TB surveil-
lance and DST for SLD is needed, as well as increased 
laboratory capacity across European countries.
Introduction
Extensively drug-resistant tuberculosis (XDR TB) is 
a worldwide threat to TB control, as XDR TB cases 
are extremely difficult to treat [1]. The origin of XDR 
TB is linked to the introduction of second-line anti-
tuberculosis drugs (SLD) for the treatment of multid-
rug-resistant tuberculosis (MDR TB) and the possible 
mismanagement of patients (including failure of com-
pliance) under SLD treatment [2,3]. In March 2006, the 
term XDR TB first appeared in the literature in a United 
States Centers for Disease Control and Prevention (US 
CDC) report describing the findings of a worldwide 
survey on anti-TB drug resistance carried out between 
2000 and 2004 [4]. Since then, a number of scientific 
and media reports on XDR TB have been published 
[5]. Although the term has emerged only recently, the 
occurrence of TB cases resistant to most available 
drugs is not new [6]. The definition of XDR TB, MDR TB 
plus resistance to a fluoroquinolone and at least one of 
three injectable SLD (amycacin, kanamycin, capreomy-
cin) has been revised in 2006 because not all the SLD 
included in the original case definition were used and 
tested worldwide [7-9]. 
Epidemics of drug-resistant TB have been described in 
the WHO European Region since the 1990s [10]. XDR TB 
has been identified as a significant problem in coun-
tries of the former Soviet Union [11] and the potential 
threat of XDR TB for Europe has been assessed by the 
European Centre for Disease Centre and Prevention 
(ECDC) in 2006 [12]. The occurrence of XDR TB out-
breaks in patients co-infected with HIV has re-enforced 
the public health awareness, with a particular focus on 
South Africa [13]. 
In 2005, the EuroTB network started a molecular 
surveillance project on MDR TB in 24 countries of 
the WHO European Region including 19 European 
Union (EU) Member States, plus Croatia, Israel, the 
Former Yugoslav Republic of Macedonia, Norway and 
Switzerland) [14]. The project was coordinated by 
EuroTB in France and the National Institute for Public 
Health and the Environment (RIVM) in the Netherlands 
until the end of 2007. As resistance to SLD was already 
a matter of concern in 2005, data on drug susceptibil-
ity testing (DST) for SLD were collected in addition to 
DNA fingerprint data [14,15]. The project provided an 
opportunity to implement case reporting of XDR TB by 
applying the revised XDR TB case definition of 2006 
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retrospectively. This article describes notification data 
on resistance to SLD in the EU and some neighbouring 
countries from January 2003 through June 2007.
Methods 
Data collection
The MDR TB project included 24 countries of the WHO 
European Region that were able to or planning to par-
ticipate in case-based reporting of molecular data on 
MDR TB cases at European level in 2005. Case-based 
data on all newly diagnosed and culture confirmed 
positive MDR TB cases were reported by national 
surveillance institutions (NSI) to EuroTB on a quarterly 
basis from January 2005 through June 2007. Data for 
2003 and 2004 were reported retrospectively. The data 
were collected anonymously, according to a standard-
ised data file specification reviewed by the members 
of the EuroTB advisory committee [16]. Each case had 
a unique record identifier. Common definitions of vari-
ables were used by the participating countries, includ-
ing demographic and clinical variables and results from 
susceptibility testing for first and second-line anti-TB 
drugs. The country of origin of a case was defined as 
Table 1










Amikacin Kanamycin Capreomycin Ciprofloxacin Ofloxacin
N (%) N (%) N (%) N (%) N (%)
Five second line anti-tuberculosis drugs tested
France2 152 5 148 (97) 147 (97) 135 (89) 145 (95) 149 (98)
Czech Republic1 38 5 25 (66) 22 (58) 25 (66) 25 (66) 25 (66)
Norway1 11 5 11 (100) 11 (100) 11 (100) 5 (45) 11 (100)
Ireland1 8 5 3 (38) 1 (13) 3 (38) 3 (38) 1 (13)
Slovenia4 3 5 3 (100) 1 (33) 1 (33) 3 (100) 1 (33)
Four second line anti-tuberculosis drugs tested
Lithuania3 656 4 89 (14) 173 (26) 101 (15) - - 172 (26)
Estonia2 248 4 245 (99) 245 (99) 244 (98) - - 245 (99)
Israel2 45 4 43 (96) - - 43 (96) 44 (98) 44 (98)
Switzerland1 25 4 24 (96) - - 9 (36) 4 (16) 19 (76)
Denmark3 5 4 5 (100) - - 5 (100) 5 (100) 5 (10)
Three second line anti-tuberculosis drugs tested
Latvia1 712 3 - - 705 (99) 698 (98) - - 689 (97)
Romania3 50 3 19 (38) 44 (88) - - 44 (88) - -
Belgium1 31 3 12 (39) 2 (6) - - - - 12 (39)
Poland4 17 3 6 (35) - - 6 (35) - - 6 (35)
Former Yugoslavian Republic 
of Macedonia1
15 3 8 (53) - - 8 (53) 8 (53) - -
Cyprus1 3 3 1 (33) - - 3 (100) - - 3 (10)
 Two second line anti-tuberculosis drugs tested
The Netherlands2 34 2 33 (97) - - - - 34 (100) - -
Croatia2 5 2 1 (20) - - - - 2 (40) - -
One second line anti-tuberculosis drug tested
Spain3 50 1 - - 2 (4) - - - - - -
Sweden1 21 1 15 (71) - - - - - - - -
Total 2,129   691 (51) 1,353 (69) 1,292 (67) 322 (82) 1382 (71)
DST: drug sensitivity testing; MDR TB: multidrug-resistant tuberculosis.
1 Data reported between 2003 and 2007. 
2 Data reported between 2003 and 2005. 
3 Data reported between 2004 and 2005.  
4 Data reported in 2005 and 2006 in Poland ; 2003 and  2005 in Cyprus; 2003, 2005 and  2006 in Slovenia.
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their country of birth (if available) or their country of 
citizenship.
Reporting of drug susceptibility testing for 
second-line drugs and XDR TB cases
DST results for SLD, resistant or susceptible, were col-
lected for the following drugs: amikacin, kanamycin, 
capreomycin, ciprofloxacin, ofloxacin. The rationale 
behind the choice of the SLD tested was that they rep-
resented the most commonly used aminoglycosides 
(injectables) and fluoroquinolones. If no resistance is 
measured against the tested drugs within each of these 
two classes of drugs, it is unlikely that resistance can 
be found against other drugs from the same classes, 
because of cross-resistance. Data were validated by 
EuroTB, eventually completed by the reporting NSI and 
collated into a European MDR TB case database.
The revised 2006 XDR TB case definition was used 
for the analysis [8]. This definition refers to XDR TB 
as resistance to at least isoniazid and rifampicin 
as well as further resistance to a fluoroquinolone 
(ofloxacin, ciprofloxacin) and at least one second-line 
injectable aminoglycocide (amikacin, kanamycin and 
capreomycin). 
The number and distribution of MDR TB isolates tested 
for anti-TB second-line DST as well as the number and 
proportion of XDR TB cases by country were calculated. 
The percentage of SLD tested (SLD testing percentage) 
for a given country was defined as the number of tests 
performed for a specific drug divided by the number of 
MDR TB cases reported in that country. The proportion 
of XDR TB cases was calculated using the number of 
MDR TB cases tested for SLD (included in the XDR TB 
definition) as a denominator.
As reported by EuroTB [17], anti-TB drug resistance sur-
veillance (DRS) was performed on nationwide samples 
of TB cases in all 18 countries participating to the MDR 
TB project [14], except for Italy and Spain (partial cov-
erage) and Poland (no information about representa-
tiveness available). Data from Romania was provided 
from a country-wide DST survey. 
The number of MDR TB cases reported to the project 
was compared with the number of MDR TB cases 
reported to Euro-TB using drug resistance susceptibil-
ity data.
Table 2
Distribution of MDR and XDR TB cases by country reported in 18 European countries, 2003-20071
Country (number of TB cases 
reported to EuroTB) 
MDR TB cases reported  to 
MDR TB project 
N
MDR TB  isolates tested for 
2-5 SLD  
N (%)
  XDR TB cases 
N 
XDR among MDR TB  cases 
with SLD  DST 
%
Countries with at least 88% of MDR TB cases tested for two to five SLD 
Latvia (6,107) 712 688 (97) 53 8
Estonia (1,736) 248 245 (99) 58 24
France (16,986) 152 149 (98) 1 1
Romania (60,323) 50 44 (88) 2 5
Israel (1,454) 45 44 (98) 2 5
Netherlands (3,820) 34 33 (97) 1 3
Switzerland (2,303) 25 22 (88) 0 0
Norway (1,221) 11 11 (100) 0 0
Denmark (1,200) 5 5 (100) 0 0
Slovenia (1,049) 3 3 (100) 1 33
Cyprus (102) 3 3 (100) 0 0
Total 1,288 1,247 (97) 118 9%
Countries with less than 88% of MDR TB cases tested for two to five SLD 
Lithuania (5,088) 656 173 (26) 25 14
Czech Republic (4199) 38 25 (66) 5 20
Belgium (4,187) 31 12 (39) 0 0
Poland (17,873) 17 6 (35) 0 0
Macedonia (2,662) 15 8 (53) 0 0
Ireland (1,747) 8 3 (38) 1 33
Croatia (3,931) 5 1 (20) 0 0
Total 770 228 (30) 31 14%
Total 2,058 1,475 (72) 149 10%
DST: drug sensitivity testing; MDR TB: multidrug-resistant tuberculosis, XDR TB: extensively drug-resistant tuberculosis; SLD: second line 
drugs.
1 Data reported for at least one year between 2003 and 2007.
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Results
Individual data on SLD testing for Mycobacterium
tuberculosis isolates from 2,129 cases reported 
between January 2003 and July 2007 were available 
for 20 countries (population of 259,467,657) out of 
24 European countries (population of 467,007,506), 
including 15 EU countries. Data were not reported by 
Germany, Italy, Finland and the United Kingdom, repre-
senting almost half of the total population covered by 
the surveillance project. 
Sixteen additional MDR TB cases were reported by the 
MDR TB surveillance system when compared with the 
number of routinely reported MDR TB cases to EuroTB 
in ten countries with representative data reported dur-
ing three consecutive years (2003-2005) (i.e. Belgium, 
Denmark, Estonia, Ireland, Israel, Latvia, Netherlands, 
Norway, Slovenia, Switzerland) [17]. 
Number of second-line anti-TB drugs 
tested for susceptibility by country
The number of SLD tested varied from one to five by 
country (Table 1). 
In the five countries where SLD testing was reported for 
all five drugs; France, Czech Republic, Norway, Ireland, 
and Slovenia, the proportion of MDR TB cases tested 
(SLD testing percentages) varied from ≥ 13% in Ireland 
to ≥ 58% in the Czech Republic, and ≥ 89% in France. In 
countries where DST was performed for four SLD, cip-
rofloxacin was not tested in Lithuania and Estonia, and 
kanamycin was not tested in Israel, Switzerland, and 
Denmark. Testing percentages were very high (≥ 96%) 
in Estonia and Israel for all the SLD tested. In contrast, 
testing percentages were low in Lithuania (≤ 26%). 
In the six countries where DST was performed for three 
drugs, amikacin was included in testing practices in 
all the countries, except in Latvia. DST was performed 
for two drugs (amikacin and ciprofloxacin) in the 
Netherlands (testing percentage ≥ 97%) and Croatia 
(testing percentage ≤ 40%). Two countries, Sweden and 
Spain tested for one SDL.
In six countries (Norway, Ireland, Slovenia, Denmark, 
Cyprus and Croatia), the numbers of MDR TB cases 
reported was small and therefore the results for those 
countries do not necessarily reflect the testing prac-
tices in these countries.
XDR TB cases reported by country
The number of XDR TB cases was calculated for the 
18 countries where MDR TB isolates were tested for 
at least two SLD (Table 2). When considering the pro-
portion of MDR TB cases tested for SLD, two groups of 
countries could be distinguished: group 1, countries 
with a high (≥ 88%) percentage of SLD testing and 
group 2, countries with a low (≤ 88%) percentage of 
SLD testing (Table 2). The ten countries in group 1 rep-
resented 63% (1,288/2,058) of reported MDR TB cases 
and 79% of the identified XDR TB cases.
XDR TB cases were detected in 10 countries, of which 
nine are EU Member States, and seven belonged to 
group 1. The overall proportion of XDR TB cases among 
MDR TB cases with DST for SLD was 10%. Ninety-one 
percent (136/149) of the XDR TB cases detected were 
reported in the Baltic States, where the percentage of 
XDR TB among MDR TB patients tested for SLD was 8% 
or higher (Table 2). In Estonia, 24% of MDR TB cases 
with DST results for SLD were XDR. This percentage 
is based on a highly representative sample of 99% of 
MDR TB patients tested for SLD. Therefore, this result 
indicates a relatively high prevalence of XDR TB among 
MDR TB cases in this country. In Latvia, where SLD 
results were available for 97% of MDR TB, the propor-
tion of XDR TB was three times lower than in Estonia. 
In Lithuania, the proportion of XDR TB (14%) was based 
on a sample of 173 MDR TB cases with DST results. 
These 173 patients represent 26% of all reported MDR 
TB cases, which may not have been selected randomly 
meaning that only the most severe cases may have 
been tested for SLD. In the Czech Republic, the per-
centage of XDR TB cases was relatively high (20%), but 
the information for SLD testing was only available for 
25 cases, representing 66% of the Czech MDR TB cases 
reported to our project.
Discussion
This surveillance-based project provides baseline 
data on XDR TB in a large number of European coun-
tries at the time of the establishment of the XDR TB 
case definition. Although four western European coun-
tries with a large population were not included in this 
project, results show that at least one XDR TB case 
was reported in 10 out of 18 European countries. The 
overall proportion of XDR TB among 1,475 (72%) MDR 
TB patients tested for SLD was approximately 10%. 
Ninety-one percent of the reported 149 XDR TB cases 
were notified by the three Baltic countries (Estonia: 
248 cases, Latvia: 712 cases, Lithuania: 656 cases), 
which belonged to the former Soviet Union until 2004. 
This confirms the finding of a worldwide survey con-
ducted by WHO and the US CDC, showing that the pro-
portion of XDR TB among TB patients originating from 
former Soviet Union countries is high. [18]. 
These data have to be interpreted in a broader scope of 
the establishment of TB surveillance and control in the 
WHO European Region [19,20]. The number of XDR TB 
cases detected can partly be affected by differences in 
surveillance systems between countries for case defi-
nitions, the possibility of linking laboratory and noti-
fication data, and by data quality (completeness and 
validity). The revision of the XDR TB definition had an 
impact on the determination of the number of XDR TB 
cases in European countries [8]. According to the previ-
ous case definition, the proportion of XDR among MDR 
TB cases was estimated to be higher in 17 countries 
[12].
The fact that 20 out of 24 participating countries 
reported SLD test results for at least one drug, and that 
5www.eurosurveillance.org
DST for SLD was performed but not available for report-
ing in at least one other country, the United Kingdom, is 
a positive indicator for the availability of DST for SLD at 
European level. However, the number of XDR TB cases 
reported could be underestimated because of the lim-
ited number of SLD susceptibility testing in some coun-
tries or over-estimated due to lack of standardisation. 
The number and type of SLD tested varied considerably 
between countries. A lack of standardisation and homo-
geneity in drug susceptibility testing practices for SLD 
has been identified by a panel of laboratory experts 
[21]. However, susceptibility testing of SLD has yielded 
reliable and reproducible results for some of the SLD 
[22]. Cross-resistance is common among aminoglyco-
sides and absolute among fluoroquinolones, however, 
not all isolates exhibit the same resistance profile. 
Despite issues related to cross-resistance, it remains 
important to test a broad panel of SLD [23].  At the time 
of reporting, SLD DST methods had not been standard-
ised or recommended, and External Quality Assurance 
(EQA) was not available, but since 2007 EQA for SLD 
has begun and since 2008 policy guidance has been 
published, which should help in standardising testing 
practices [21]. Therefore, it is expected that SLD DST 
practices and standardisation of these will improve 
significantly within the coming years.
The findings of this project and previous ones [14,18] 
concerning the relatively high rate of 10% XDR among 
MDR TB cases, should have an impact on clinical man-
agement of individual patients and TB control, espe-
cially in eastern European countries. There is a need 
for new drugs and treatment strategies. However, 
while new drugs will only be available in a number of 
years, the utility of derivates of current drugs and also 
alternative drugs like meropenem should be explored 
[24]. Serious consequences for TB control may be 
related to increased travel and migration, as this can 
lead to imported cases MDR TB from eastern Europe to 
western Europe, and transmissible forms of MDR and 
XDR TB are a fearsome scenario [14]. If transmission of 
XDR TB is diagnosed in western European countries, 
new strategies on monitoring risks associated with 
immigration from and travel to high-incidence settings 
should be developed.
Our surveillance project has some limitations that 
should be taken into account in future MDR and XDR 
TB surveillance in Europe. It would be of considerable 
value if data from the four missing countries could be 
added. In countries with a low proportion of patients 
tested for SLD, (Lithuania, Czech Republic), additional 
data is needed to better interpret the XDR TB preva-
lence. In countries with low numbers of XDR TB cases 
reported (e.g. Ireland and Slovenia), XDR TB percent-
ages can be biased and therefore should not be com-
pared to other countries. 
Conclusion
Further research are conducted on the occurrence of 
transmitted MDR and XDR TB strains to investigate 
whether they pose a new evolutionary development of 
M. tuberculosis, or an extend of the current problem. 
Both scenarios would highlight consequences of a long 
lasting, uncontrolled problem and demonstrate the 
need for enhanced efforts in TB control in the regions 
where this problem develops. The capacity for SLD test-
ing should be upgraded, especially in areas with high 
numbers of drug-resistant TB cases, such as in eastern 
Europe. As identified in a previous survey [25], stand-
ardisation and quality assurance of laboratory meth-
ods for DST of SLD should be improved across Europe. 
An EU reference laboratory network has been estab-
lished with EU Member States to support their activi-
ties [26]. Surveillance data on MDR and XDR TB with 
improved quality are essential to determine the mag-
nitude of this threat to TB control. In addition, surveil-
lance data is needed to monitor TB control activities, 
and as a basis for implementing appropriate treatment 
and care and to prioritise laboratory resources.
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